Name of the Issue: Alkem Laboratories Limited

1	**Type of Issue**	Initial Public Offer
2	**Issue Size (Rs. Mn)**	13,466.22*
		13,477.64**

**Source: Prospectus dated December 15, 2015*

*** Source: Basis of Allotment- pursuant to spill over of undersubscription in Employee category to Net offer*

3	**Grade of issue along with name of the rating agency**	
	Name	NA
	Grade	NA
4	**Subscription Level (Number of times)**	30.87 *

** Figure is before technical rejections and after adjusting for cheque return cases*

Source: Minutes for basis of allotment dated December 19, 2015

5 **QIB Holding (as a %age of Outstanding Capital) as disclosed to the stock exchanges**

Particulars	%age
(i) On Allotment **	5.30%
(ii) at the end of the 1st Quarter immediately after the listing of the issue (December 31, 2015)	6.04%
(iii) at the end of 1st FY (March 31, 2016)	6.81%
(iv) at the end of 2nd FY (March 31, 2017)***	6.75%
(v) at the end of 3rd FY (March 31, 2018) ***	6.92%

** QIB Holding not disclosed as reporting for relevant period has not been completed.*

Source:

*** Minutes for basis of allotment dated December 19, 2015*

**** Represents Instiutional holdings as per Clause 31 of LODR*

6 **Financials of the issuer**

(Rs. Million)

Parameters	1st FY (March 31,2016)	2nd FY (March 31,2017) #	3rd FY (March 31,2018) #
Income from operations	49,915	58,525	64,312
Net Profit for the period	6,731	8,815	6,195
Paid-up equity share capital	239	239	239
Reserves excluding revaluation reserves	34,787	44,437	48,399

** Financials not available as reporting for the relevant years has not been completed.*

 # As per IND AS

Source: Stock Exchange Filings. Annual Reports.

7 Trading Status

The equity shares of Alkem Laboratories Limited are listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") (and together with BSE the "Stock Exchanges")

The equity shares have not been suspended or delisted.

Particulars	Status
(i) at the end of 1st FY (March 31, 2016)	Frequently Traded
(ii) at the end of 2nd FY (March 31, 2017)	Frequntly Traded on NSE & infrequently traded on BSE
(iii) at the end of 3rd FY (March 31, 2018)	Infrequently Traded

Source: Stock exchange data.

8 Change in Directors of Issuer from the disclosures in the offer document

Particulars	Name of Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2016)	-	-
(ii) at the end of 2nd FY (March 31, 2017) #	Dr. Dheeraj Sharma	Appointed
	Mr. Mangaldas Chhaganlal Shah	Resigned
(iii) at the end of 3rd FY (March 31, 2018)	Dheeraj Sharma- appointed as	Appointed
	Sandeep Singh appointed as	Appointed

[#] *Changes in Directors updated till June 15, 2017*

Source: Prospectus dated December 15, 2015

9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document	Not applicable as 100% offer for sale
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

10 Status of utilization of issue proceeds

(i) As disclosed in the offer document	Not applicable as 100% offer for sale
(ii) Actual utilization	Not applicable
(iii) Reasons for deviation, if any	Not applicable

11 Comments of monitoring agency, if applicable

(i) Comments on use of funds	Not applicable
(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document	Not applicable
(iii) Any other reservations expressed by the monitoring agency about the end use of funds	Not applicable

12 Pricing Data

Designated Stock Exchange	BSE
Issue Price (Rs.)	1050.00 *
Listing Date	23-Dec-15

** Discount of Rs.100 was offered to Eligible Employees of the Issuer*

Price parameters	At close of listing day- Decemner 23, 2015	Close of 30th calendar day from listing day - January 21, 2016(1)	Close of 90th calendar day from listing day - March 21, 2015(2)	As at the end of the 1st FY after the listing of the issue (31st March,2016)		
				Closing price	High	Low
Market Price	1,381.5	1,368.0	1,347.5	1,366.5	1,589.0	1,232.0
S&P BSE Sensex*	25850.3	23,962.2	25,285.4	25,341.9	29,094.6	22,494.6
S&P BSE Healthcare*	16,715.7	15,173.5	15,441.7	15,149.3	18,842.7	14,418.9

Price parameters	As at the end of the 2nd FY after the listing of the issue (31st March,2017)			As at the end of the 3rd FY after the listing of the issue (31st March,2018)		
	Closing price	High	Low	Closing price	High	Low
Market Price	2,207.0	2,228.6	2,152.6	1,926.1	1,983.0	1,920.0
S&P BSE Sensex*	29,620.5	29,687.6	29,552.6	33,255.4	33,289.3	32,997.9
S&P BSE Healthcare*	15,312.4	15,345.6	15,283.5	13,484.0	13,501.7	13,208.5

** Being index of BSE, the designated stock exchange*

(1) 30th calender day has been taken as listing date plus 29 calender days. Where the 30th day is a holiday the immediately following trading day has been considered

(2) 90th calender day has been taken as listing date plus 89 calender days.Where the 90th day is a holiday the immediately following trading day has been considered

(3) The pricing data is not disclosed as the relevant fiscal years have not been completed

13 Basis for Issue Price

Accounting ratio		As disclosed in offer document*	At the end of 1st FY (March 31,2016)	At the end of 1st FY (March 31,2017)	At the end of 1st FY (March 31,2018)
EPS (Basic)	***Alkem Laboratories Limited***	38.7	56.30	74.61	52.77
	Peer Group				
	Torrent Pharmaceuticals Limited	44.4	101.78	50.48	40.07
	Ipca Laboratories Limited	20.1	7.39	15.42	18.97
	Alembic Pharmaceuticals Limited	15.0	38.16	21.39	21.89
	Industry Avg	***26.5***	***49.11***	***29.10***	***26.98***
P/E[(1)]	***Alkem Laboratories Limited***	27.1	24.27	29.58	36.50
	Peer Group				
	Torrent Pharmaceuticals Limited	34.8	13.16	30.69	31.14
	Ipca Laboratories Limited	38.8	78.45	40.42	34.52
	Alembic Pharmaceuticals Limited	45.2	15.74	29.16	25.12
	Industry Avg	***39.60***	***35.78***	***33.42***	***30.26***
RoNW	***Alkem Laboratories Limited***	15%	19.2%	19.7%	12.7%
	Peer Group				
	Torrent Pharmaceuticals Limited	30%	50.8%	21.3%	14.7%
	Ipca Laboratories Limited	12%	4.08%	8.0%	9%
	Alembic Pharmaceuticals Limited	32%	45.0%	21.1%	19%
	Industry Avg	***25%***	***33%***	***17%***	***14%***
NAV per share	***Alkem Laboratories Limited***	250.5	292.95	373.66	406.84
	Peer Group				
	Torrent Pharmaceuticals Limited	147.2	200.29	263.23	273.09
	Ipca Laboratories Limited	175.0	180.98	194.53	213.04
	Alembic Pharmaceuticals Limited	46.9	84.90	100.85	117.77
	Industry Avg	***123.0***	***155.4***	***186.2***	***201.3***

Notes

** Sourced from Prospectus dated December 15, 2015.*

(1) At the Issue Price of Rs.1050 divided by EPS (Basic).

14 Any other material information

Particulars	Date	Remarks
Some of the promoters of Alkem Laboratories Limited (“Company”) comprising of Mr. Samprada Singh and his lineal descendants, Mr. Balmiki Prasad Singh, Mrs. Manju Singh, Mr. Sarandhar Singh, Mr. Srinivas Singh, Mr. Satish Kumar Singh, Mrs. Premlata Singh, Mr. Sarvesh Singh, Mrs. Annapurna Singh, Mr. Sandeep Singh and Mrs. Inderjit Arora; and the Samprada Singh HUF have entered into a family settlement on March 23, 2016 with a view to ensure preservation of the shareholding and control of the Company within the family. Pursuant to the family settlement, the aforementioned members of the family will transfer their shareholding to a family trust. The transfer to the trust will be done only after receipt of an exemption under the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 from the Securities and Exchange Board of India. It is to be noted that such an arrangement will not result in any change in management and control of the Company.	23-Mar-16	
Favourable Competition Appellate Tribunal Order - Penalty of Rs. 746.3 million set aside"	10-May-16	
Alkem announces closure of UK-MHRA inspection for its Bioequivalence Facility at Taloja".	07-Jun-16	
Alkem announced certain restructuring of responsibilities between the senior management of the Company. The Joint Managing Directors and Executive Director would be responsible for the following functional areas of the Company’s business: - Mr. Dhananjay Kumar Singh, Joint Managing Director, shall be responsible for specific Domestic Business units focusing on Acute and Chronic Therapies in addition to support functions namely Legal and Secretarial, Purchase, Distribution & Logistics and Human Resources. - Mr. Sandeep Singh, Joint Managing Director, shall be responsible for International Business, R & D including Biotech, Finance, Quality & Compliance, API and Formulation Manufacturing facilities for International Business. - Mr. Mritunjay Kumar Singh, Executive Director, shall be responsible for certain Domestic Business units focusing on Acute and Chronic Therapies, Generics and Healthcare in addition to Strategy & Business Development and Manufacturing Facilities for Domestic Business. - Mr. Dhananjay Kumar Singh, Mr. Sandeep Singh and Mr. Mritunjay Kumar Singh shall report to Executive Chairman for their respective functional areas of business. - Mr. Prabhat Agrawal, Chief Executive Officer, shall be responsible for the overall day to day operations of the Company and report to Mr. Dhananjay Kumar Singh, Mr. Sandeep Singh and Mr. Mritunjay Kumar Singh for their abovesaid respective roles and responsibilities.	27-Jun-16	
Successful US FDA Inspection at Alkem's Bioequivalence Facility at Taloja where no 483s were issued	11-Aug-16	
Alkem Laboratories Ltd has informed BSE that US FDA had conducted an inspection at the Company’s manufacturing facility located at Daman, India from September 20 to September 29, 2016. In this regard, the Company has received the inspection report which contains thirteen 483 observations. The Company shall put together a detailed response with adequate corrective and preventive measures to address the US FDA Observations and the same is proposed to be filed within the timeline stipulated by US FDA.	29-Sep-16	
Alkem Laboratories Ltd has informed BSE that the US FDA had conducted a Bio-analytical Inspection at the Company’s manufacturing facility located at Daman, India from October 24 to October 28, 2016. The inspection has been cleared successfully without any 483 observations. This inspection was based on an ANDA filed by the Company.	28-Oct-16	
Alkem Laboratories Ltd has informed BSE that US FDA had conducted an inspection at the Company’s API (Active Pharmaceutical Ingredient) manufacturing facility located at Ankleshwar, India from 5th December to 9th December, 2016. In this regard, the Company has received the inspection report which contains three 483 observations. The Company shall put together a detailed response with adequate corrective and preventive measures to address the US FDA Observations and the same is proposed to be filed within the timeline stipulated by US FDA	12-Dec-16	

Particulars	Date	Remarks
In furtherance to the intimation captioned "Update on US FDA Inspection at Alkem's Daman Facility" dated 291h September, 2016, this is to inform you that the US FDA has issued an Establishment Inspection Report (EIR) for its Daman formulation facility which was inspected in September 2016. The inspection has now been closed by the US FDA. In response to the Form 483 issued by the US FDA, the Company had submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines. The US FDA has reviewed the CAPA and has found them acceptable	23-Dec-16	
Alkem Laboratories Ltd has informed BSE regarding a Press Release dated February 07, 2017 titled "Alkem enters into an alliance with Haw Par to exclusively market, sell and distribute Tiger Balm range of products in India".	07-Feb-17	
Update on US FDA Inspection at Alkem's Baddi Facility This is to inform you that US FDA had conducted an inspection at the Company's manufacturing facility located at Baddi, India from 2nd March, 2017 to 10th March, 2017. In this regard, the Company has received the inspection report which contains three 483 observations. The Company shall put together a detailed response with adequate corrective and preventive measures to address the US FDA Observations and the same is proposed to be filed within the timeline stipulated by US FDA. Kindly take note of the same	10-Mar-17	
In furtherance to the intimation captioned 'Update on US FDA Inspection at Alkem's Ankaleshwar API Facility' dated 12th December, 2016, this is to inform you that the US FDA has issued an Establishment Inspection Report (EIR) for the Company's Active Pharmaceutical Ingredient (API) manufacturing facility located at Ankaleshwar, India which was inspected in December 2016. The inspection has now been closed by the US FDA. In response to the Form 483 issued by the US FDA, the Company had submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines. The US FDA has reviewed the CAPA and has found them acceptable. A copy of Press Release is enclosed herewith for your information. Kindly take the same on record	29-Mar-17	
The board of the Company has approved execution of the amended and restated shareholders' agreement on March 29, 2017, to be entered into amongst the Company and the promoter shareholders.	29-Mar-17	
In furtherance to the intimation captioned 'Update on US FDA Inspection at Alkem's Baddi Facility' dated 10th March, 2017, this is to inform you that the US FDA has issued an Establishment Inspection Report (EIR) for its Baddi manufacturing facility which was inspected in March 2017. The inspection has now been closed by the US FDA. In response to the Form 483 issued by the US FDA, the Company had submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines. A copy of Press Release is enclosed herewith for your information. Kindly take the same on record	23-May-17	
US FDA had conducted an inspection at the Company's manufacturing facility located at Baddi, India from 11th September, 2017 to 15th September, 2017.In this regard, the Company has received the inspection report which contains two 483 observations. The Company shall put together a detailed response with adequate corrective and preventive measures to address the US FDA Observations and the same is proposed to be filed within the timeline stipulated by US FDA	18-Sep-17	
Alkem Laboratories Ltd has informed BSE that Mr. Sandeep Singh, Joint Managing Director of the Company has been appointed and re-designated as the "Managing Director" for a period of five years with immediate effect subject to approval by the shareholders of the Company. Further, Mr. Sandeep Singh is the grandson of Mr. Samprada Singh, Chairman Emeritus of the Company. Further a proposal has also been considered by the Board of Directors that for the smooth transition of Board powers, as and when the Executive Chairman of	17-Oct-17	

Particulars	Date	Remarks
Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that Mr. Prabhat Agrawal has resigned from the position of Chief Executive Officer & Key Managerial Personnel of the Company due to personal reasons. Mr. Prabhat Agrawal shall continue upto 31st March, 2018 for smooth transition of responsibilities to senior management.	30-Oct-17	
In furtherance to the intimation captioned "Update on US FDA Inspection at Alkem's Baddi Facility" dated 18th September, 2017, this is to inform you that US FDA has issued an Establishment Inspection Report (EIR) for the Company's manufacturing facility located at Baddi, India which was inspected from 11th September, 2017 to 15th September, 2017. In response to the two Form 483 observations issued by the US FDA, the Company had submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines. The inspection has now been closed by the US FDA.	10-Jan-18	
This is to inform you that the US FDA had conducted an inspection at the Company's manufacturing facility located at Amaliya, Daman, India from 19th March, 2018 to 27th March, 2018. Post the inspection, the Company has received a Form 483 with thirteen observations. The Company shall put together a detailed response with adequate corrective and preventive measures to address the US FDA observations and the same is proposed to be filed within the timeline stipulated by the US FDA. Further to this, please also be informed that the US FDA had conducted an inspection at the Company's manufacturing facility located at St. Louis, USA from 12th March, 2018 to 16th March, 2018. In response to the one Form 483 observation issued by the US FDA, the Company has submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines.	28-Mar-18	
In furtherance to the intimation captioned "US FDA Inspection at Alkem's manufacturing facility located at Amaliya, Daman" dated 28th March, 2018, this is to inform you that US FDA has issued an Establishment Inspection Report (EIR) for the Company's manufacturing facility located at Amaliya, Daman, India which was inspected from 19th March, 2018 to 27th March, 2018. In response to the Form 483 issued by the US FDA containing thirteen observations, the Company had submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines. The inspection has now been closed by the US FDA.	24-Jul-18	
Board of Directors in their meeting held today, i.e. 8th February, 2019, considered the request received from Mr. Nawal Kishore Singh, part of the Promoter Group of the Company, for re-classification as a public shareholder in accordance with Regulation 31A of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 ('Listing Regulations').	08-Feb-19	